News

Intense public scrutiny of drug safety issues is prompting FDA to take a closer look at its program for establishing Risk Evaluation and Mitigation Strategies. Healthcare providers, as well as pharmaceutical companies, believe that the program is being overused, raising costs, and interfering with patient treatment.

Agents in late-stage development for pulmonary disease.

A new case-control study nested within a large database of human immunodeficiency virus (HIV)-infected patients found abacavir initiation was associated with increased odds of having a myocardial infarction, while longer exposure to abacavir was not.

Platelet response to clopidogrel (Plavix) may be enhanced by concomitant use of agents that induce cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2), according to research presented during the 39th annual meeting of the American College of Clinical Pharmacology, Baltimore.

New biologic: Alpha-1-proteinase inhibitor (human) for injection (Glassia) was approved for the treatment of chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1-proteinase inhibitor.

Atrial fibrillation (AF) is the most common form of arrhythmia, affecting an estimated 2.2 million people in the United States. The goal of treatment is to reduce symptoms through rate or rhythm control and to prevent a cardioembolic event. Dronedarone (pronounced droe'' ne' da rone) is a noniodinated benzofuran derivative with characteristics of all 4 Vaughan-Williams antiarrhythmic classes. A search in clinicaltrials.gov for dronedarone phase 3 studies yielded 5 randomized controlled studies that investigated the efficacy and safety of the drug.

Recent FDA Approvals (through August/September 2010) related to Gilenya, Prolia, Krystexxa, Faslodex, Protopam Chloride, Ozurdex, Suboxone Film, Saphris, Tekamlo, Beyaz.

Tocilizumab (Actemra), an interleukin-6 receptor inhibitor, may be effective in the treatment of patients with rheumatoid arthritis who have an inadequate response to anti-tumor necrosis factor-α therapy, according to research presented here at the 39th annual meeting of the American College of Clinical Pharmacology, Baltimore.

Non-Hodgkin's lymphoma (NHL) has several subtypes, with subtle variations, which leads to reduced effectiveness of standardized therapies. The introduction of rituximab, which targets B-cells, has had a positive effect on the management of NHL, but much still needs to be accomplished.

New combination: Dutasteride and tamsulosin (Jalyn) was approved by FDA for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

The bigger obstacle to overcome will be the general lack of understanding of the healthcare system

Aging baby boomers will bring more people into Medicare, while reform will expand Medicaid

Republicans introduced a bill to abolish Medicare's Independent Payment Advisory Board (IPAB) before it even gets off the ground

For health reform to be a success, employers must continue to provide healthcare benefits

Beyond basic compliance with the regulations, the market fallout could be anything from a pin drop to a sonic boom

Navigating legal issues to create the best possible program sometimes requires a delicate balancing act by plan sponsors

The empowered patient is one change that stands above all others

Provider groups are on task to create accountable care organizations (ACOs), and many believe they will change the delivery of healthcare

Most existing benefit plans will lose their grandfathered status by 2019, according to observers

Many fear that the $5 billion allocated by the federal government for high-risk insurance pools won't last until 2014

Now is the time for collaboration of payers, billers and providers to lead the industry by reducing inefficiencies

A cumulative 23% cut is scheduled for this December. Another 6.5% cut in January 2011 and a 2.9% cut in January 2012 are scheduled.

The stimulus package provided more than $1 billion in federal support for comparative effectiveness research (CER), which has the potential to improve clinical decision making

The significant challenges facing insurers include minimizing disruption and mitigating the impact on cost

It will be critical to have appropriate awareness campaigns in the area of palliative and hospice care services

The Board of Directors of Blue Cross Blue Shield of Massachusetts (BCBSMA) has chosen Executive Vice President Andrew Dreyfus as the company's new president and chief executive officer. Dreyfus succeeds Bill Van Faasen who has served in an unpaid interim role of president and CEO since March 16, 2010.

Consumer driven health plans (CDHPs) in the U.S. experienced continued growth this year, albeit at a slower rate than in 2009, according to preliminary results released by United Benefit Advisors (UBA) from its "2010 UBA Health Plan Survey."

Though the debate and eventual passage of the Patient Protection and Affordable Care Act (PPACA) filled news cycles for months, the bill ? and healthcare in general ? are so complex that plans have been working overtime to explain the many provisions of the new law.